Intas launches trastuzumab biosimilar to treat breast cancer

• Intas Pharmaceuticals announced Wednesday that it launched its trastuzumab biosimilar, under the brand name Eleftha, in India, reported Business Standard.

• According to the company, its biosimilar breast cancer therapy could help cut down the cost of treatment by 65 percent.

• The maximum retail price (MRP) of Eleftha will be Rs 19 995 for a dose strength of 440 mg, Intas stated.

• The MRP of most of trastuzumab brands in India currently ranges between Rs 58 000 and Rs 63 000 per 440 mg vial, the company noted.

• In patients with HER2-positive early breast cancer, almost 18 cycles of trastuzumab-based therapy are required, Intas said, adding that the launch of Eleftha will reduce the cost of the treatment to less than Rs 4 lakh.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.